Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12206.154 | 0.9855 | 0.9713 | 1.0125 | |
| MDA-MB-134-VI | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12206.154 | 0.9579 | 0.9167 | 1.0125 | |
| MDA-MB-134-VI | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12206.154 | 0.9960 | 0.9920 | 1.0125 | |
| MDA-MB-134-VI | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12206.154 | 0.8528 | 0.7089 | 1.0125 | |
| MDA-MB-134-VI | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12206.154 | 0.6724 | 0.3513 | 1.0125 | |
| MDA-MB-134-VI | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12206.154 | 0.5851 | 0.1780 | 1.0125 | |
| MDA-MB-134-VI | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12206.154 | 0.3953 | -0.2003 | 1.0125 | |
| MDA-MB-134-VI | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12206.154 | 0.0786 | -0.8377 | 1.0125 | |
| MDA-MB-157 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12594.167 | 1.0318 | 1.0449 | 1.4099 | |
| MDA-MB-157 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12594.167 | 1.0124 | 1.0175 | 1.4099 | |
| MDA-MB-157 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12594.167 | 0.9547 | 0.9354 | 1.4099 | |
| MDA-MB-157 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12594.167 | 1.0257 | 1.0363 | 1.4099 | |
| MDA-MB-157 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12594.167 | 1.0953 | 1.1334 | 1.4099 | |
| MDA-MB-157 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12594.167 | 0.6701 | 0.5056 | 1.4099 | |
| MDA-MB-157 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12594.167 | 0.3424 | -0.0649 | 1.4099 | |
| MDA-MB-157 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12594.167 | 0.3070 | -0.1345 | 1.4099 | |
| MDA-MB-157 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12594.167 | 0.0051 | -0.9527 | 1.4099 | |
| MDA-MB-175-VII | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000256 | uM | 10642.142 | 1.0190 | 1.0767 | 0.5006 | |
| MDA-MB-175-VII | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00128 | uM | 10642.142 | 0.9580 | 0.8358 | 0.5006 | |
| MDA-MB-175-VII | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0064 | uM | 10642.142 | 1.0332 | 1.1349 | 0.5006 | |
| MDA-MB-175-VII | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.032 | uM | 10642.142 | 1.0091 | 1.0365 | 0.5006 | |
| MDA-MB-175-VII | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.16 | uM | 10642.142 | 0.8951 | 0.6029 | 0.5006 | |
| MDA-MB-175-VII | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.8 | uM | 10642.142 | 0.8773 | 0.5397 | 0.5006 | |
| MDA-MB-175-VII | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 4 | uM | 10642.142 | 0.6679 | -0.1071 | 0.5006 | |
| MDA-MB-175-VII | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 20 | uM | 10642.142 | 0.2927 | -0.8282 | 0.5006 |